|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Trading: BUY @ $0.092
Signal Strength: STRONG
Indicator is best used in conjunction with additional indicators as it has the ability to highlight potential overbought or oversold levels. This indicator utilizes upper and lower bands to visually represent price extremes associated with the bands. Additional value can be added to the trading strategy by accessing divergences between price and volume.
Impedimed (ASX:IPD) is currently Oversold highlighting the potential for a short term trend reversal in the upward direction.
Acceleration bands serve as a trading envelope using an instrument’s typical volatility over a standard setting of 20 bars. The user may change the input (close) period length and multiplier factor.
Calculation: Acceleration Bands:
1) Upper band = ( High * ( 1 + 2 * (((( High – Low )/(( High + Low ) / 2 )) * 1000 ) * Factor )));
2) Lower band = ( Low * ( 1 – 2 * (((( High – Low )/(( High + Low ) / 2 )) * 1000 ) * Factor )));
3) Where Factor=0.001
PROFILE: Impedimed (IPD.AX)
Stock Exchange: ASX
Ticker Codes: | IPD.AX | ASX:IPD |
ImpediMed Limited, together with its subsidiaries, engages in the development, manufacture, and sale of bioimpedance devices and consumables in Australia, North America, Europe, and internationally. The company operates through Medical and Test & Measurement segments. It offers L-Dex U400, a technology that utilizes the characteristics of frequency dependent current flow to quantify changes in extracellular fluid in the patient's limb; and SFB7, a tetra polar bioimpedance spectroscopy device that scans various frequencies for the estimation of body composition in healthy individuals. The company also provides DF50, a single frequency body composition analysis in healthy individuals; and ImpediVET, a bioimpedance spectroscopy technology for use in veterinary applications. Its products are used in a range of applications, such as in the assessment and monitoring of secondary lymphedema, as well as monitoring of body composition and hydration. In addition, the company is involved in the supply of power precision testing and measuring equipment. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.
|MNS Milnes Holdings||0.08||7.1||959,142||-15.91||BEARISH|
|ALK Alkane Exploration||0.91||6.5||4,762,492||-11.5||BEARISH|
|ABC Adelaide Brighton||3.06||6.3||4,642,840||-3.64||BEARISH|
|APE Ap Eagers Holdings||9.01||6.1||633,117||-2.28||BEARISH|
|RFG Retail Food||0.1||5.4||3,641,364||-3.85||BEARISH|
|FDV Frontier Digital Ventures||1||5.3||159,343||-7.43||BEARISH|
|LYC Lynas Corporation||2||5||8,370,794||-9.41||BEARISH|